Glaukos Past Earnings Performance

Past criteria checks 0/6

Glaukos's earnings have been declining at an average annual rate of -35.6%, while the Medical Equipment industry saw earnings growing at 13.6% annually. Revenues have been growing at an average rate of 9.5% per year.

Key information

-35.6%

Earnings growth rate

-31.9%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate9.5%
Return on equity-29.2%
Net Margin-42.8%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 69% Above Its Share Price

Feb 21
Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 69% Above Its Share Price

Is Glaukos (NYSE:GKOS) A Risky Investment?

Jan 21
Is Glaukos (NYSE:GKOS) A Risky Investment?

Glaukos: Remains A Hold Due To High Valuation And Negative Profitability

Jan 09

Glaukos Corporation's (NYSE:GKOS) 27% Jump Shows Its Popularity With Investors

Dec 20
Glaukos Corporation's (NYSE:GKOS) 27% Jump Shows Its Popularity With Investors

Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Nov 03
Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Oct 05
Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Glaukos: Continued Growth Rates, Regulatory Tailwinds, And Support

Sep 01

Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Jun 28
Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Glaukos: Revising To Buy On These 3 Catalytic Factors

Jun 16

Risks To Shareholder Returns Are Elevated At These Prices For Glaukos Corporation (NYSE:GKOS)

Apr 19
Risks To Shareholder Returns Are Elevated At These Prices For Glaukos Corporation (NYSE:GKOS)

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Feb 19
Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Glaukos: Trial Momentum Building, Profitability Differentials Yet To Pull Through

Feb 14

Glaukos sees positive data from mid-stage trial of dry eye treatment

Jan 10

Glaukos: Show Me The Money

Nov 10

Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Oct 16
Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Glaukos pays $10M upfront to license iVeena's eye disorder therapy IVMED-80

Aug 24

Glaukos: Gross Margins Compressing Despite FY22 Guidance Revision

Aug 04

Glaukos gains as Stifel upgrades to Buy citing 2022 sales upside

Jul 12

Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Jun 28
Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Mar 14
Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Nov 29
Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Is Glaukos (NYSE:GKOS) Weighed On By Its Debt Load?

Aug 15
Is Glaukos (NYSE:GKOS) Weighed On By Its Debt Load?

Revenue & Expenses Breakdown
Beta

How Glaukos makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NYSE:GKOS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23315-135226137
30 Sep 23304-129215136
30 Jun 23297-126208131
31 Mar 23289-139205130
31 Dec 22283-99195121
30 Sep 22285-90190113
30 Jun 22288-56187113
31 Mar 22294-28182106
31 Dec 21294-50179101
30 Sep 21294-3817695
30 Jun 21284-6017186
31 Mar 21238-8316481
31 Dec 20225-12017185
30 Sep 20218-7316684
30 Jun 20211-7116981
31 Mar 20238-3716879
31 Dec 192371517768
30 Sep 19225-1914761
30 Jun 19211-1213657
31 Mar 19195-1212753
31 Dec 18181-1312050
30 Sep 18169-1411347
30 Jun 18165-610644
31 Mar 18163-410241
31 Dec 1715909639
30 Sep 17151-19136
30 Jun 17140-18434
31 Mar 1712757431
31 Dec 1611456529
30 Sep 1610225728
30 Jun 1691-15126
31 Mar 1680-354827
31 Dec 1572-374425
30 Sep 1566-404124
30 Jun 1559-393623
31 Mar 1552-93020
31 Dec 1446-122819
30 Sep 1438-112418
30 Jun 1433-122217
31 Mar 1426-132016
31 Dec 1321-131716

Quality Earnings: GKOS is currently unprofitable.

Growing Profit Margin: GKOS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: GKOS is unprofitable, and losses have increased over the past 5 years at a rate of 35.6% per year.

Accelerating Growth: Unable to compare GKOS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GKOS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (8.7%).


Return on Equity

High ROE: GKOS has a negative Return on Equity (-29.16%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.